Literature DB >> 15685371

Temporal control of Cre recombinase-mediated in vitro DNA recombination by Tet-on gene expression system.

Zhong-Min Guo1, Kang Xu, Ying Yue, Bing Huang, Xin-Yan Deng, Nü-Qi Zhong, Xun Hong, Xi-Gu Chen, Dong Xiao.   

Abstract

Conditional gene expression and gene deletion are important experimental approaches for examining the functions of particular gene products in mouse models. These strategies exploiting Cre-mediated site-specific DNA recombination have been incorporated into transgenic and gene-targeting procedures to allow in vivo manipulation of DNA in embryonic stem cells (ES cells) or living animals. The Cre/lox P system has become widely used in conditional gene targeting, conditional gene repair and activation, inducible chromosome translocation, and chromosome engineering. In this project, we have employed the universal transgenic system and the liver-specific promoter system for tightly temporal and liver-specific control of Cre gene expression in mice that (1) integrates the advantages of the Tet-on gene expression system and Cre/lox P site-mediated gene activation, and (2) simplifies the scheme of animal crosses through a combination of two control elements in a single transgene. A liver-specific apoE promoter was inserted into the promoter cloning site upstream of the rtTA cassette of pCore construct to generate the transgene construct pApoErtTA-tetO-Cre, followed by demonstrating stringent regulation of doxycycline (Dox)-induced Cre-mediated recombination in the lox P-flanked transcription STOP cassette-modified BEL-7402 cells. That is to say, in the absence of Dox, the Cre gene is not expressed and will not induce site-specific recombination between two lox P sites, whereas on exposure to Dox, the Cre gene will be expressed and the recombination will occur. Together, these data indicate that the Tet-on gene expression system is able to successfully and stringently control Cre expression in vitro, which lays a solid foundation for efficient and spatio-temporal Cre gene activation in transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685371

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  6 in total

1.  A photoactivatable Cre-loxP recombination system for optogenetic genome engineering.

Authors:  Fuun Kawano; Risako Okazaki; Masayuki Yazawa; Moritoshi Sato
Journal:  Nat Chem Biol       Date:  2016-10-10       Impact factor: 15.040

2.  ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.

Authors:  Rebecca S Cook; Joan T Garrett; Violeta Sánchez; Jamie C Stanford; Christian Young; Anindita Chakrabarty; Cammie Rinehart; Yixian Zhang; Yaming Wu; Lee Greenberger; Ivan D Horak; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

3.  Neurodegeneration and early lethality in superoxide dismutase 2-deficient mice: a comprehensive analysis of the central and peripheral nervous systems.

Authors:  S S Oh; K A Sullivan; J E Wilkinson; C Backus; J M Hayes; S A Sakowski; E L Feldman
Journal:  Neuroscience       Date:  2012-04-16       Impact factor: 3.590

Review 4.  Getting Down to Specifics: Profiling Gene Expression and Protein-DNA Interactions in a Cell Type-Specific Manner.

Authors:  Colin D McClure; Tony D Southall
Journal:  Adv Genet       Date:  2015-07-23       Impact factor: 1.944

5.  Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Authors:  Christian D Young; Adam D Pfefferle; Philip Owens; María G Kuba; Brent N Rexer; Justin M Balko; Violeta Sánchez; Hailing Cheng; Charles M Perou; Jean J Zhao; Rebecca S Cook; Carlos L Arteaga
Journal:  Cancer Res       Date:  2013-04-30       Impact factor: 12.701

Review 6.  Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain.

Authors:  Brandon J Walters; Amber B Azam; Colleen J Gillon; Sheena A Josselyn; Iva B Zovkic
Journal:  Front Genet       Date:  2016-01-12       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.